Source: Eur Respir J, 53 (2) 1801128; 10.1183/13993003.01128-2018
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Gabrielle Fröberg, Lena Jansson, Judith Bruchfeld. Treatment of latent tuberculosis with 12 weeks isoniazid/rifapentine in clinical practice. Eur Respir J, 53 (2) 1801128; 10.1183/13993003.01128-2018

Member's Comments

No comment yet.

Related content which might interest you: Treatment of latent tuberculosis infection with 6 months isoniazid therapy in pediatric population Source: Eur Respir J 2005; 26: Suppl. 49, 624s Year: 2005 Clinical characteristics and treatment outcomes of patients with pulmonary tuberculosis with delayed conversion over 4 months Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015 Outcomes of treatment of latent tuberculosis infection in children with two different regimens Source: Eur Respir J 2006; 28: Suppl. 50, 487s Year: 2006 Systematic review of shorter 2-3 months regimens for treatment of latent tuberculosis Source: Annual Congress 2013 –Epidemiological and public health features of tuberculosis Year: 2013 Comparison of compliance of two therapeutic regimens in treatment of latent tuberculosis infection in Belgrade children Source: Eur Respir J 2004; 24: Suppl. 48, 648s Year: 2004 Benefit of treatment of latent tuberculosis infection in individual patients Source: Eur Respir J 2016; 47:1592-1594 Year: 2016 Benefit of treatment of latent tuberculosis infection in individual patients Source: Eur Respir J 2015; 46: 1397-1406 Year: 2015 Benefit of treatment of latent tuberculosis infection in individual patients Source: Eur Respir J 2016; 47:1594-1595 Year: 2016 Multidrug-resistant tuberculosis: treatment outcome after 18 months of invidualised therapy Source: Eur Respir J 2001; 18: Suppl. 33, 314s Year: 2001 Tolerability of rifapentine-based regimens in latent tuberculosis infection treatment in the elderly Source: Eur Respir J, 53 (3) 1802396; 10.1183/13993003.02396-2018 Year: 2019 Impact of smoking on outcome of treatment of tuberculosis in patients taking intermittent treatment of tuberculosis under India‘s revised tuberculosis control program Source: Annual Congress 2008 - Health effects of passive smoking and of a smoking ban Year: 2008 A choice of regimen improves completion for patients with latent TB infection Source: Breathe 2008; 4: 366 Year: 2008 Clinical indicators of treatment response to Mepolizumab at 12 weeks Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 The assessment of the efficacy of a standard chemotherapy regimen in the treatment of new sputum-positive tuberculosis (TB) patients Source: Eur Respir J 2001; 18: Suppl. 33, 340s Year: 2001 Bedaquiline-containing regimens for chronic XDR-TB patients: up to 120 weeks after initiation Source: International Congress 2017 – MDRTB: detection and management Year: 2017 A novel nurse-led approach improves treatment completion rates for latent tuberculosis infection (LTBI) treatment Source: International Congress 2014 – Mycobacterium tuberculosis infection: new therapeutic approaches Year: 2014 The characteristics of previous tuberculosis treatment programmes in patients with tuberculosis relapses Source: Eur Respir J 2001; 18: Suppl. 33, 473s Year: 2001 When do we extend the treatment of tuberculosis (TB) more than 6 months? Source: Annual Congress 2007 - Clinical tuberculosis Year: 2007 Evaluation of new smear positive tuberculosis patients 5 years after initiation of treatment under a DOTS programme Source: Annual Congress 2010 - Tuberculosis epidemiology Year: 2010 Prevalence, screening and treatment of latent tuberculosis among oral corticosteroid recipients Source: Eur Respir J 2014; 44: 1373-1375 Year: 2014